AbbVie vs. Johnson & Johnson: Which Healthcare Stock Is a Better Buy in 2026?

AbbVie generated FY2025 revenue of $61.2B, up 9%, and is projected to lift sales to $67.2B and net income from $4.2B to $14.6B this year, supported by Skyrizi, Rinvoq and its Apogee Therapeutics acquisition. Johnson & Johnson reported $94.2B in FY2025 revenue, up 6%, with net income rising to $26.8B from $14.1B; current-year revenue is expected to reach $101B. AbbVie trades at a lower 18.8x forward P/E versus J&J's 23.5x, offering greater potential upside but with higher patent-expiry, product concentration, leverage and drug-pricing risks, while J&J offers stronger diversification and profitability but faces talc litigation and Orthopedics separation costs.

Analysis

ABBV’s reported negative equity is not, by itself, a near-term solvency signal; accumulated buybacks and acquisition accounting can make debt-to-equity economically unhelpful for mature pharma. The relevant underwriting question is whether post-dividend free cash flow can fund business-development spending while preserving leverage capacity. If the earnings step-up implied by current expectations is delivered, ABBV’s multiple should be assessed against a materially higher cash-earnings base, whereas a miss would expose how much of the growth narrative relies on a narrow set of franchise assets and deal execution.

JNJ offers a different catalyst path: separation of Orthopedics could unlock a higher-quality Innovative Medicine/MedTech mix, but the market may withhold full credit until separation costs, stranded overhead and litigation reserve requirements are quantified. The more non-obvious beneficiary of continued branded-drug volume growth is MCK rather than CAH: scale and specialty-distribution mix give MCK better operating leverage and manufacturer-service economics, while distributor customer concentration is less likely to translate into meaningful pricing power over ABBV. Consensus may be overstating ABBV’s headline valuation discount versus JNJ without adjusting for FDA, reimbursement and integration binary risk; JNJ’s premium is defensible if the separation reduces conglomerate discount and legal cash outflows remain bounded.

Key Decisions for Investors

• Prefer a 3-6 month long ABBV / short JNJ pair only if ABBV’s next quarterly guidance confirms immunology and neuroscience growth sufficient to support the implied earnings inflection. Target a 10-15% relative return; exit if ABBV cuts full-year EPS or revenue guidance, or if key growth-franchise demand decelerates materially.
• For lower-beta healthcare exposure, accumulate JNJ on weakness ahead of detailed Orthopedics separation disclosures; size as a 6-18 month catalyst position rather than a litigation trade. Falsifier: settlement/reserve developments that require a material upward revision to expected cash outflows, or separation economics showing substantial stranded costs.
• Maintain MCK as the preferred distribution read-through versus CAH over 6-12 months, contingent on specialty-drug volume and manufacturer-services margin holding. Avoid treating ABBV’s wholesale concentration as a direct short catalyst for either distributor absent evidence of contract repricing or inventory-working-capital deterioration.
• Do not underwrite APGE as a standalone M&A read-through until transaction terms, closing conditions and ABBV’s accounting treatment are independently verified; monitor for acquisition-related EPS dilution and R&D expense guidance rather than extrapolating strategic claims into near-term earnings.